We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Theravance Biopharma, Inc. (TBPH - Free Report) incurred a loss of $1.17 per share in fourth-quarter 2019, wider than the Zacks Consensus Estimate of $1.11 and also the year-ago loss of 92 cents.
However, total revenues of $29.5 million in the quarter beat the Zacks Consensus Estimate of $18 million. Revenues also soared 87.9% year over year, mainly owing to an upfront payment from Pfizer (PFE - Free Report) for rights to its skin-selective pan-JAK inhibitor program. Also, higher revenues from the collaboration agreement with Mylan benefitted the top-line.
Total revenues in the fourth quarter comprised collaboration revenues worth $9.6 million from Johnson & Johnson (JNJ - Free Report) and $9.9 million received from Mylan.
Notably, Theravance has collaboration with Mylan for the development and commercialization of Yupelri (revefenacin), approved by the FDA in November 2018. The drug is used for maintenance treatment of adults with chronic obstructive pulmonary disease (COPD). Theravance and Mylan formally launched their sales and marketing efforts for Yupelri in early 2019 and the product witnessed a strong initial sales uptake thereafter.
On the fourth-quarter conference call, management stated that Yupelri witnessed a strong customer acceptance and brand performance across key market metrics. The company also informed that as of October 2019, Yupelri achieved 86% share of the nebulized LAMA market and a 10.7% stake of the long-acting nebulized market including the DME market.
Shares of Theravance have lost 5.2% in the past year compared with the industry’s decrease of 3.8%.
Quarter in Detail
Research & development expenses were $67 million, up 28.1% from the year-ago quarter, primarily due to higher employee-related expenses and higher external cost.
Selling, general & administrative expenses escalated 29.4% to $33 million due to higher share-based compensation.
As of Dec 31, 2019, Theravance had cash, cash equivalents, marketable securities of $285.8 million compared with $352.9 million as of Sep 30, 2019.
Full-Year Results
For 2019, Theravance’s revenues of $73.4 million were up 21.5% year over year.
Loss per share was $4.25 in 2019 compared with the loss of $3.99 in 2018.
Product & Pipeline Updates
Notably, Theravance has an economic interest in royalties earned from GlaxoSmithKline on triple combination COPD treatment Trelegy Ellipta’s global sales. In the fourth quarter, Glaxo recorded sales of $221.5 million from Trelegy Ellipta. Theravance is eligible to receive 5.5-8.5% (tiered) of the product's worldwide net sales.
Theravance also has a collaboration pact with Johnson & Johnson’s subsidiary Janssen to develop its JAK inhibitor, TD-1473, for the treatment of inflammatory intestinal diseases. A phase II study on TD-1473 for treating Crohn's disease and a phase IIb/III study for ulcerative colitis are ongoing. Data from the phase IIb portion of the ulcerative colitis and phase II Crohn's disease studies is expected in late 2020.
Additionally, the company is developing TD-5202 (gut-selective irreversible JAK3 inhibitor) in a phase I study for addressing inflammatory intestinal diseases. Along with the earnings release, Theravance announced encouraging results from the phase I study on TD-5202. Data from the single-ascending dose and multiple-ascending dose studies, which evaluated the safety and tolerability of TD-5202, showed that TD-5202 was generally well tolerated in healthy patients.
Theravance is evaluating ampreloxetine (TD-9855) in two phase III programs for treating patients with symptomatic neurogenic orthostatic hypotension (nOH).
The company is developing the inhaled, lung-selective pan-Janus kinase (JAK) inhibitor, TD-8236, in a phase I study for treating inflammatory lung diseases with minimal systemic exposure. In December 2019, the company dosed the first patient in a phase II allergen challenge study on TD-8236 to address inflammatory lung diseases with data from the same expected in mid-2020.
2020 Outlook
For the full year, Theravance anticipates operating loss (excluding non-cash share-based compensation) in the range of $205-$225 million.
Theravance Biopharma, Inc. Price, Consensus and EPS Surprise
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Theravance (TBPH) Q4 Earnings Miss, Revenues Beat Estimates
Theravance Biopharma, Inc. (TBPH - Free Report) incurred a loss of $1.17 per share in fourth-quarter 2019, wider than the Zacks Consensus Estimate of $1.11 and also the year-ago loss of 92 cents.
However, total revenues of $29.5 million in the quarter beat the Zacks Consensus Estimate of $18 million. Revenues also soared 87.9% year over year, mainly owing to an upfront payment from Pfizer (PFE - Free Report) for rights to its skin-selective pan-JAK inhibitor program. Also, higher revenues from the collaboration agreement with Mylan benefitted the top-line.
Total revenues in the fourth quarter comprised collaboration revenues worth $9.6 million from Johnson & Johnson (JNJ - Free Report) and $9.9 million received from Mylan.
Notably, Theravance has collaboration with Mylan for the development and commercialization of Yupelri (revefenacin), approved by the FDA in November 2018. The drug is used for maintenance treatment of adults with chronic obstructive pulmonary disease (COPD). Theravance and Mylan formally launched their sales and marketing efforts for Yupelri in early 2019 and the product witnessed a strong initial sales uptake thereafter.
On the fourth-quarter conference call, management stated that Yupelri witnessed a strong customer acceptance and brand performance across key market metrics. The company also informed that as of October 2019, Yupelri achieved 86% share of the nebulized LAMA market and a 10.7% stake of the long-acting nebulized market including the DME market.
Shares of Theravance have lost 5.2% in the past year compared with the industry’s decrease of 3.8%.
Quarter in Detail
Research & development expenses were $67 million, up 28.1% from the year-ago quarter, primarily due to higher employee-related expenses and higher external cost.
Selling, general & administrative expenses escalated 29.4% to $33 million due to higher share-based compensation.
As of Dec 31, 2019, Theravance had cash, cash equivalents, marketable securities of $285.8 million compared with $352.9 million as of Sep 30, 2019.
Full-Year Results
For 2019, Theravance’s revenues of $73.4 million were up 21.5% year over year.
Loss per share was $4.25 in 2019 compared with the loss of $3.99 in 2018.
Product & Pipeline Updates
Notably, Theravance has an economic interest in royalties earned from GlaxoSmithKline on triple combination COPD treatment Trelegy Ellipta’s global sales. In the fourth quarter, Glaxo recorded sales of $221.5 million from Trelegy Ellipta. Theravance is eligible to receive 5.5-8.5% (tiered) of the product's worldwide net sales.
Theravance also has a collaboration pact with Johnson & Johnson’s subsidiary Janssen to develop its JAK inhibitor, TD-1473, for the treatment of inflammatory intestinal diseases. A phase II study on TD-1473 for treating Crohn's disease and a phase IIb/III study for ulcerative colitis are ongoing. Data from the phase IIb portion of the ulcerative colitis and phase II Crohn's disease studies is expected in late 2020.
Additionally, the company is developing TD-5202 (gut-selective irreversible JAK3 inhibitor) in a phase I study for addressing inflammatory intestinal diseases. Along with the earnings release, Theravance announced encouraging results from the phase I study on TD-5202. Data from the single-ascending dose and multiple-ascending dose studies, which evaluated the safety and tolerability of TD-5202, showed that TD-5202 was generally well tolerated in healthy patients.
Theravance is evaluating ampreloxetine (TD-9855) in two phase III programs for treating patients with symptomatic neurogenic orthostatic hypotension (nOH).
The company is developing the inhaled, lung-selective pan-Janus kinase (JAK) inhibitor, TD-8236, in a phase I study for treating inflammatory lung diseases with minimal systemic exposure. In December 2019, the company dosed the first patient in a phase II allergen challenge study on TD-8236 to address inflammatory lung diseases with data from the same expected in mid-2020.
2020 Outlook
For the full year, Theravance anticipates operating loss (excluding non-cash share-based compensation) in the range of $205-$225 million.
Theravance Biopharma, Inc. Price, Consensus and EPS Surprise
Theravance Biopharma, Inc. price-consensus-eps-surprise-chart | Theravance Biopharma, Inc. Quote
Zacks Rank
Theravance currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>